Patents by Inventor Shinya Ishii

Shinya Ishii has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240158482
    Abstract: An objective of the present invention is to provide methods for promoting antigen uptake into cells by antigen-binding molecules, methods for increasing the number of times of antigen binding by one antigen-binding molecule, methods for promoting reduction of the antigen concentration in plasma by administering antigen-binding molecules, and methods for improving the plasma retention of an antigen-binding molecule, as well as antigen-binding molecules that allow enhanced antigen uptake into cells, antigen-binding molecules having an increased number of times of antigen binding, antigen-binding molecules that can promote reduction of the antigen concentration in plasma when administered, antigen-binding molecules with improved plasma retention, pharmaceutical compositions comprising the above antigen-binding molecules, and methods for producing them. The present inventors revealed that the above objective can be achieved by using antigen-binding molecules that show calcium-dependent antigen-antibody reaction.
    Type: Application
    Filed: December 20, 2023
    Publication date: May 16, 2024
    Applicant: Chugai Seiyaku Kabushiki Kaisha
    Inventors: Tomoyuki Igawa, Shinya Ishii, Miho Funaki, Naoka Hironiwa, Atsuhiko Maeda, Junichi Nezu, Yoshinao Ruike, Takeshi Baba, Shun Shimizu
  • Publication number: 20240150465
    Abstract: The present inventors discovered novel multispecific antigen-binding molecules with excellent cellular cytotoxicity, which comprise a first domain comprising a first antigen variable region which binds to DLL3 and a second domain comprising a second antigen variable region which binds to T cell receptor complex. The present inventors prepared further bispecific antibodies, and assessed their T cell-dependent cell cytotoxicity (TDCC), and found that they also show strong TDCC activity. Since the molecules/antibodies of the present invention show a strong cytotoxicity against cells expressing DLL3, novel pharmaceutical compositions comprising the molecules/antibodies for treating or preventing various cancers associated with DLL3 can be provided.
    Type: Application
    Filed: May 2, 2023
    Publication date: May 9, 2024
    Inventors: Shogo KAMIKAWAJI, Yasuko KINOSHITA, Shinya ISHII
  • Patent number: 11891434
    Abstract: An objective of the present invention is to provide methods for promoting antigen uptake into cells by antigen-binding molecules, methods for increasing the number of times of antigen binding by one antigen-binding molecule, methods for promoting reduction of the antigen concentration in plasma by administering antigen-binding molecules, and methods for improving the plasma retention of an antigen-binding molecule, as well as antigen-binding molecules that allow enhanced antigen uptake into cells, antigen-binding molecules having an increased number of times of antigen binding, antigen-binding molecules that can promote reduction of the antigen concentration in plasma when administered, antigen-binding molecules with improved plasma retention, pharmaceutical compositions comprising the above antigen-binding molecules, and methods for producing them. The present inventors revealed that the above objective can be achieved by using antigen-binding molecules that show calcium-dependent antigen-antibody reaction.
    Type: Grant
    Filed: May 24, 2018
    Date of Patent: February 6, 2024
    Assignee: Chugai Seiyaku Kabushiki Kaisha
    Inventors: Tomoyuki Igawa, Shinya Ishii, Miho Funaki, Naoka Hironiwa, Atsuhiko Maeda, Junichi Nezu, Yoshinao Ruike, Takeshi Baba, Shun Shimizu
  • Publication number: 20240010738
    Abstract: The present invention provides pharmaceutical compositions comprising second-generation molecules that are superior than TOCILIZUMAB, by altering the amino acid sequences of the variable and constant regions of TOCILIZUMAB, which is a humanized anti-IL-6 receptor IgG1 antibody, to enhance the antigen-neutralizing ability and increase the pharmacokinetics, so that the therapeutic effect is exerted with a less frequency of administration, and the immunogenicity, safety and physicochemical properties (stability and homogeneity) are improved. The present invention also provides methods for producing these pharmaceutical compositions. The present inventors have successfully generated second-generation molecules that are superior to TOCILIZUMAB by appropriately combining amino acid sequence alterations in the CDR domains, variable regions, and constant regions.
    Type: Application
    Filed: September 11, 2023
    Publication date: January 11, 2024
    Applicant: Chugai Seiyaku Kabushiki Kaisha
    Inventors: Tomoyuki Igawa, Shinya Ishii, Atsuhiko Maeda, Mika Sakurai, Tetsuo Kojima, Tatsuhiko Tachibana, Hirotake Shiraiwa, Hiroyuki Tsunoda, Yoshinobu Higuchi
  • Publication number: 20240002836
    Abstract: The present inventors discovered that antibodies having weaker antigen-binding activity at the early endosomal pH in comparison with that at the pH of plasma are capable of binding to multiple antigen molecules with a single antibody molecule, have long half-lives in plasma, and have improved durations of time in which they can bind to antigen.
    Type: Application
    Filed: January 18, 2023
    Publication date: January 4, 2024
    Inventors: Tomoyuki IGAWA, Shinya ISHII, Atsuhiko MAEDA, Takashi NAKAI
  • Publication number: 20230220066
    Abstract: The present disclosure provides multispecific antigen-binding molecules capable of binding to CD3 and CD137 (4-1BB) but not binding to CD3 and CD137 at the same time, and capable of binding to CLDN6. The multispecific antigen-binding molecules of the present disclosure exhibit enhanced T-cell dependent cytotoxicity activity in a CLDN6-dependent manner through binding to the CD3/CD37 and CLDN6. The present invention provides multi-specific antigen-binding molecules and pharmaceutical compositions thereof that can be used for targeting cells expressing CLDN6, for use in immunotherapy for treating various cancers, especially those associated with CLDN6 such as CLDN6-positive cancers.
    Type: Application
    Filed: March 30, 2021
    Publication date: July 13, 2023
    Inventors: Shinya ISHII, Naoki KIMURA, Tatsushi KODAMA
  • Publication number: 20230220083
    Abstract: An objective of the present invention is to provide methods for facilitating antigen-binding molecule-mediated antigen uptake into cells, methods for facilitating the reduction of antigen concentration in plasma, methods for increasing the number of antigens to which a single antigen-binding molecule can bind, methods for improving pharmacokinetics of antigen-binding molecules, antigen-binding molecules improved for facilitated antigen uptake into cells, antigen-binding molecules capable of facilitating the reduction of antigen concentration in plasma, antigen-binding molecules capable of repeatedly binding to antigens, antigen-binding molecules with improved pharmacokinetics, pharmaceutical compositions comprising such an antigen-binding molecule, and methods for producing those described above.
    Type: Application
    Filed: November 3, 2022
    Publication date: July 13, 2023
    Applicant: Chugai Seiyaku Kabushiki Kaisha
    Inventors: Tomoyuki IGAWA, Shinya ISHII, Atsuhiko MAEDA, Takashi NAKAI
  • Publication number: 20230203108
    Abstract: The present invention relates to granzyme B variants with increased protease activities and/or increased resistance against inhibitors; polynucleotides encoding the granzyme B variants; cells expressing the granzyme B variants; pharmaceutical compositions containing cells expressing the granzyme B variants; and pharmaceutical compositions containing the granzyme B variants. In some embodiments, the pharmaceutical compositions may be used in combination with cells expressing chimera receptors and/or antigen-binding molecules.
    Type: Application
    Filed: May 28, 2021
    Publication date: June 29, 2023
    Applicant: Chugai Seiyaku Kabushiki Kaisha
    Inventors: Yasunori Komori, Tomoyuki Igawa, Atsushi Narita, Shinya Ishii
  • Publication number: 20230203144
    Abstract: The present invention provides a combination of two or more isolated or purified anti-C5 antibodies, wherein the isolated or purified anti-C5 antibodies bind to an epitope within the beta chain or alpha chain of C5 and wherein the isolated or purified anti-C5 antibodies to be combined do not compete with each other for binding to the epitope. Methods of using the combination for treating an individual having a complement-mediated disease or condition which involves excessive or uncontrolled activation of C5, or for enhancing the clearance of C5 from plasma in an individual, are also provided.
    Type: Application
    Filed: November 29, 2022
    Publication date: June 29, 2023
    Inventors: Eriko MURATA, Shinya ISHII, Tomoyuki IGAWA, Yuji HORI, Norihito SHIBAHARA
  • Patent number: 11667713
    Abstract: The present inventors discovered novel multispecific antigen-binding molecules with excellent cellular cytotoxicity, which comprise a first domain comprising a first antigen variable region which binds to DLL3 and a second domain comprising a second antigen variable region which binds to T cell receptor complex. The present inventors prepared further bispecific antibodies, and assessed their T cell-dependent cell cytotoxicity (TDCC), and found that they also show strong TDCC activity. Since the molecules/antibodies of the present invention show a strong cytotoxicity against cells expressing DLL3, novel pharmaceutical compositions comprising the molecules/antibodies for treating or preventing various cancers associated with DLL3 can be provided.
    Type: Grant
    Filed: December 28, 2018
    Date of Patent: June 6, 2023
    Assignee: Chugai Seiyaku Kabushiki Kaisha
    Inventors: Shogo Kamikawaji, Yasuko Kinoshita, Shinya Ishii
  • Publication number: 20230159648
    Abstract: The present invention provides pharmaceutical compositions comprising second-generation molecules that are superior than TOCILIZUMAB, by altering the amino acid sequences of the variable and constant regions of TOCILIZUMAB, which is a humanized anti-IL-6 receptor IgG1 antibody, to enhance the antigen-neutralizing ability and increase the pharmacokinetics, so that the therapeutic effect is exerted with a less frequency of administration, and the immunogenicity, safety and physicochemical properties (stability and homogeneity) are improved. The present invention also provides methods for producing these pharmaceutical compositions. The present inventors have successfully generated second-generation molecules that are superior to TOCILIZUMAB by appropriately combining amino acid sequence alterations in the CDR domains, variable regions, and constant regions.
    Type: Application
    Filed: January 12, 2023
    Publication date: May 25, 2023
    Applicant: Chugai Seiyaku Kabushiki Kaisha
    Inventors: Tomoyuki Igawa, Shinya Ishii, Atsuhiko Maeda, Mika Sakurai, Tetsuo Kojima, Tatsuhiko Tachibana, Hirotake Shiraiwa, Hiroyuki Tsunoda, Yoshinobu Higuchi
  • Publication number: 20230057904
    Abstract: The present disclosure provides antigen binding molecules that show binding activity towards Claudin-6 (CLDN6), methods for producing the antigen binding molecules, use of the antigen-binding molecules and immunoconjugates comprising the same in treating and/or preventing cancers, use of the antigen binding molecules in detecting the presence of CLDN6 in biological samples, and use of the antigen binding molecules in diagnosis of various cancers.
    Type: Application
    Filed: July 10, 2020
    Publication date: February 23, 2023
    Inventors: Naoki KIMURA, Tatsushi KODAMA, Shinya ISHII, Masaru MURAOKA, Takayuki KAMIKAWA
  • Publication number: 20220306755
    Abstract: The present invention provides pharmaceutical compositions comprising second-generation molecules that are superior than TOCILIZUMAB, by altering the amino acid sequences of the variable and constant regions of TOCILIZUMAB, which is a humanized anti-IL-6 receptor IgG1 antibody, to enhance the antigen-neutralizing ability and increase the pharmacokinetics, so that the therapeutic effect is exerted with a less frequency of administration, and the immunogenicity, safety and physicochemical properties (stability and homogeneity) are improved. The present invention also provides methods for producing these pharmaceutical compositions. The present inventors have successfully generated second-generation molecules that are superior to TOCILIZUMAB by appropriately combining amino acid sequence alterations in the CDR domains, variable regions, and constant regions.
    Type: Application
    Filed: June 1, 2022
    Publication date: September 29, 2022
    Applicant: Chugai Seiyaku Kabushiki Kaisha
    Inventors: Tomoyuki Igawa, Shinya Ishii, Atsuhiko Maeda, Mika Sakurai, Tetsuo Kojima, Tatsuhiko Tachibana, Hirotake Shiraiwa, Hiroyuki Tsunoda, Yoshinobu Higuchi
  • Patent number: 11381736
    Abstract: An image capture apparatus performs control such that when an approaching to a finder is not made, a touch operation with an area that is less than a first threshold on the touch operation surface is validated, and a touch operation with an area that is not less than the first threshold on the touch operation surface is invalidated, when the approaching to the finder is made, the touch operation with the area that is not less than the first threshold on the touch operation surface is validated even if the touch operation has the area that is not less than the first threshold on the touch operation surface.
    Type: Grant
    Filed: March 9, 2021
    Date of Patent: July 5, 2022
    Assignee: Canon Kabushiki Kaisha
    Inventor: Shinya Ishii
  • Patent number: 11371039
    Abstract: The present inventors discovered that antibodies having weaker antigen-binding activity at the early endosomal pH in comparison with that at the pH of plasma are capable of binding to multiple antigen molecules with a single antibody molecule, have long half-lives in plasma, and have improved durations of time in which they can bind to antigen.
    Type: Grant
    Filed: September 14, 2020
    Date of Patent: June 28, 2022
    Assignee: Chugai Seiyaku Kabushiki Kaisha
    Inventors: Tomoyuki Igawa, Shinya Ishii, Atsuhiko Maeda, Takashi Nakai
  • Publication number: 20220187308
    Abstract: Disclosed is a library consisting essentially of a plurality of antigen-binding molecules differing in sequence from each other, wherein an antigen-binding domain in each of the antigen-binding molecules comprises at least one amino acid residue that changes the antigen-binding activity of the antigen-binding molecule depending on ion concentration conditions. Also disclosed are a composition comprising a plurality of polynucleotide molecules each encoding the antigen-binding molecules, a composition comprising a plurality of vectors each comprising the polynucleotide molecules, a method for selecting the antigen-binding molecules, a method for isolating the polynucleotide molecules, a method for producing the antigen-binding molecules, and a pharmaceutical composition comprising any of the antigen-binding molecules.
    Type: Application
    Filed: December 22, 2021
    Publication date: June 16, 2022
    Applicant: Chugai Seiyaku Kabushiki Kaisha
    Inventors: Tomoyuki IGAWA, Shinya ISHII, Miho FUNAKI, Naoka HIRONIWA, Shun SHIMIZU
  • Patent number: 11359194
    Abstract: The present inventors discovered that antibodies having weaker antigen-binding activity at the early endosomal pH in comparison with that at the pH of plasma are capable of binding to multiple antigen molecules with a single antibody molecule, have long half-lives in plasma, and have improved durations of time in which they can bind to antigen.
    Type: Grant
    Filed: September 14, 2020
    Date of Patent: June 14, 2022
    Assignee: Chugai Seiyaku Kabushiki Kaisha
    Inventors: Tomoyuki Igawa, Shinya Ishii, Atsuhiko Maeda, Takashi Nakai
  • Publication number: 20220041741
    Abstract: The present invention provides pharmaceutical compositions comprising second-generation molecules that are superior than TOCILIZUMAB, by altering the amino acid sequences of the variable and constant regions of TOCILIZUMAB, which is a humanized anti-IL-6 receptor IgG1 antibody, to enhance the antigen-neutralizing ability and increase the pharmacokinetics, so that the therapeutic effect is exerted with a less frequency of administration, and the immunogenicity, safety and physicochemical properties (stability and homogeneity) are improved. The present invention also provides methods for producing these pharmaceutical compositions. The present inventors have successfully generated second-generation molecules that are superior to TOCILIZUMAB by appropriately combining amino acid sequence alterations in the CDR domains, variable regions, and constant regions.
    Type: Application
    Filed: October 25, 2021
    Publication date: February 10, 2022
    Applicant: Chugai Seiyaku Kabushiki Kaisha
    Inventors: Tomoyuki Igawa, Shinya Ishii, Atsuhiko Maeda, Mika Sakurai, Tetsuo Kojima, Tatsuhiko Tachibana, Hirotake Shiraiwa, Hiroyuki Tsunoda, Yoshinobu Higuchi
  • Patent number: 11243210
    Abstract: Disclosed is a library consisting essentially of a plurality of antigen-binding molecules differing in sequence from each other, wherein an antigen-binding domain in each of the antigen-binding molecules comprises at least one amino acid residue that changes the antigen-binding activity of the antigen-binding molecule depending on ion concentration conditions. Also disclosed are a composition comprising a plurality of polynucleotide molecules each encoding the antigen-binding molecules, a composition comprising a plurality of vectors each comprising the polynucleotide molecules, a method for selecting the antigen-binding molecules, a method for isolating the polynucleotide molecules, a method for producing the antigen-binding molecules, and a pharmaceutical composition comprising any of the antigen-binding molecules.
    Type: Grant
    Filed: June 18, 2018
    Date of Patent: February 8, 2022
    Assignee: Chugai Seiyaku Kabushiki Kaisha
    Inventors: Tomoyuki Igawa, Shinya Ishii, Miho Funaki, Naoka Hironiwa, Shun Shimizu
  • Publication number: 20210289126
    Abstract: An image capture apparatus performs control such that when an approaching to a finder is not made, a touch operation with an area that is less than a first threshold on the touch operation surface is validated, and a touch operation with an area that is not less than the first threshold on the touch operation surface is invalidated, when the approaching to the finder is made, the touch operation with the area that is not less than the first threshold on the touch operation surface is validated even if the touch operation has the area that is not less than the first threshold on the touch operation surface.
    Type: Application
    Filed: March 9, 2021
    Publication date: September 16, 2021
    Inventor: Shinya Ishii